The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tendor     3,4-dihydro-1H-isoquinoline- 2-carboximidamide

Synonyms: Declinax, Equitonil, Debrisoquin, Debrisoquina, Debrisoquine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Debrisoquin


Psychiatry related information on Debrisoquin


High impact information on Debrisoquin


Chemical compound and disease context of Debrisoquin


Biological context of Debrisoquin


Anatomical context of Debrisoquin

  • These studies indicate that genetically defective in vivo metabolism of debrisoquine is caused by a deficiency of a monooxygenase reaction in liver microsomes [22].
  • The formation of the 4-hydroxy metabolite from debrisoquine in hepatic microsomes from extensive metabolizers was 1.33 +/- 0.437 nmol . mg protein-1 . 15 min-1 (mean +/- SD, n = 9) [22].
  • Leukocyte DNA from "extensive metabolizers" (EMs) or "poor metabolizers" (PMs) of debrisoquine was examined by Southern analysis [23].
  • Compared with unaffected individuals, patients suffering from BEN and/or urinary tract tumors were more frequently found to have a capacity for rapid debrisoquine (DB) metabolism, a metabolic reaction related mostly to cytochrome P450 (CYP) 2D in humans [24].
  • No debrisoquin was detected in cerebrospinal fluid samples [25].

Associations of Debrisoquin with other chemical compounds


Gene context of Debrisoquin


Analytical, diagnostic and therapeutic context of Debrisoquin


  1. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Ayesh, R., Idle, J.R., Ritchie, J.C., Crothers, M.J., Hetzel, M.R. Nature (1984) [Pubmed]
  2. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Barbeau, A., Cloutier, T., Roy, M., Plasse, L., Paris, S., Poirier, J. Lancet (1985) [Pubmed]
  3. CYP2D6 genes and risk of liver cancer. Agúndez, J.A., Ledesma, M.C., Benítez, J., Ladero, J.M., Rodríguez-Lescure, A., Díaz-Rubio, E., Díaz-Rubio, M. Lancet (1995) [Pubmed]
  4. Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease. Duvoisin, R.C., Johnson, W.G. Brain Pathol. (1992) [Pubmed]
  5. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Jiménez-Jiménez, F.J., Tabernero, C., Mena, M.A., García de Yébenes, J., García de Yébenes, M.J., Casarejos, M.J., Pardo, B., García-Agundez, J.A., Benítez, J., Martínez, A. J. Neurochem. (1991) [Pubmed]
  6. Debrisoquine hydroxylase gene polymorphism (CYP2D6*4) in dementia with Lewy bodies. Huckvale, C., Richardson, A.M., Mann, D.M., Pickering-Brown, S.M. J. Neurol. Neurosurg. Psychiatr. (2003) [Pubmed]
  7. Oxidation phenotyping in alcoholics with liver disease of varying severity. Lanthier, P.L., Reshef, R., Shah, R.R., Oates, N.S., Smith, R.L., Morgan, M.Y. Alcohol. Clin. Exp. Res. (1984) [Pubmed]
  8. Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Gan, S.H., Ismail, R., Wan Adnan, W.A., Zulmi, W., Kumaraswamy, N., Larmie, E.T. British journal of clinical pharmacology. (2004) [Pubmed]
  9. Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease. Benítez, J., Barquero, M.S., Coria, F., Molina, J.A., Jiménez-Jiménez, F.J., Ladero, J.M. J. Neurol. Sci. (1993) [Pubmed]
  10. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Gough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M., Wolf, C.R. Nature (1990) [Pubmed]
  11. Lung cancer and the debrisoquine metabolic phenotype. Caporaso, N.E., Tucker, M.A., Hoover, R.N., Hayes, R.B., Pickle, L.W., Issaq, H.J., Muschik, G.M., Green-Gallo, L., Buivys, D., Aisner, S. J. Natl. Cancer Inst. (1990) [Pubmed]
  12. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Armstrong, M., Daly, A.K., Cholerton, S., Bateman, D.N., Idle, J.R. Lancet (1992) [Pubmed]
  13. Debrisoquine hydroxylation phenotyping: do we expect too much? Mitchell, S.C., Haley, C.S. Lancet (1990) [Pubmed]
  14. Relationship between plasma aldosterone and angiotensin II before and after noradrenergic inhibition in normal subjects and patients with mild essential hypertension. Beretta-Piccoli, C., Weidmann, P., Boehringer, K., Link, L., Bianchetti, M.G., Morton, J.J. J. Clin. Endocrinol. Metab. (1984) [Pubmed]
  15. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Christensen, P.M., Gøtzsche, P.C., Brøsen, K. Pharmacogenetics (1998) [Pubmed]
  16. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H.V., Meyer, U.A., Gonzalez, F.J. Pharmacogenetics (1991) [Pubmed]
  17. Cytochrome-P450-dependent hydroxylation in cluster headache. Tomson, T., Waldenlind, E., Ekbom, K. Cephalalgia : an international journal of headache. (1992) [Pubmed]
  18. Polymorphic hydroxylation of debrisoquine. Tucker, G.T., Silas, J.H., Iyun, A.O., Lennard, M.S., Smith, A.J. Lancet (1977) [Pubmed]
  19. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Yue, Q.Y., Bertilsson, L., Dahl-Puustinen, M.L., Säwe, J., Sjöqvist, F., Johansson, I., Ingelman-Sundberg, M. Lancet (1989) [Pubmed]
  20. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.L., Sjöqvist, F., Ingelman-Sundberg, M. Proc. Natl. Acad. Sci. U.S.A. (1993) [Pubmed]
  21. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Brown, M.A., Edwards, S., Hoyle, E., Campbell, S., Laval, S., Daly, A.K., Pile, K.D., Calin, A., Ebringer, A., Weeks, D.E., Wordsworth, B.P. Hum. Mol. Genet. (2000) [Pubmed]
  22. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Meier, P.J., Mueller, H.K., Dick, B., Meyer, U.A. Gastroenterology (1983) [Pubmed]
  23. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Skoda, R.C., Gonzalez, F.J., Demierre, A., Meyer, U.A. Proc. Natl. Acad. Sci. U.S.A. (1988) [Pubmed]
  24. Sex- and strain-specific induction of renal tumors by ochratoxin A in rats correlates with DNA adduction. Castegnaro, M., Mohr, U., Pfohl-Leszkowicz, A., Estève, J., Steinmann, J., Tillmann, T., Michelon, J., Bartsch, H. Int. J. Cancer (1998) [Pubmed]
  25. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Riddle, M.A., Jatlow, P.I., Anderson, G.M., Cho, S.C., Hardin, M.T., Cohen, D.J., Leckman, J.F. Neuropsychopharmacology (1989) [Pubmed]
  26. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism. Roy, S.D., Hawes, E.M., Hubbard, J.W., McKay, G., Midha, K.K. Lancet (1984) [Pubmed]
  27. Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin. Wiholm, B.E., Alvan, G., Bertilsson, L., Sawe, J., Sjöqvist, F. Lancet (1981) [Pubmed]
  28. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Relling, M.V., Evans, W.E., Fonné-Pfister, R., Meyer, U.A. Cancer Res. (1989) [Pubmed]
  29. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Wolff, T., Distlerath, L.M., Worthington, M.T., Groopman, J.D., Hammons, G.J., Kadlubar, F.F., Prough, R.A., Martin, M.V., Guengerich, F.P. Cancer Res. (1985) [Pubmed]
  30. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Kaisary, A., Smith, P., Jaczq, E., McAllister, C.B., Wilkinson, G.R., Ray, W.A., Branch, R.A. Cancer Res. (1987) [Pubmed]
  31. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., Meyer, U.A. J. Biol. Chem. (1990) [Pubmed]
  32. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. Adedoyin, A., Arns, P.A., Richards, W.O., Wilkinson, G.R., Branch, R.A. Clin. Pharmacol. Ther. (1998) [Pubmed]
  33. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Christensen, M., Tybring, G., Mihara, K., Yasui-Furokori, N., Carrillo, J.A., Ramos, S.I., Andersson, K., Dahl, M.L., Bertilsson, L. Clin. Pharmacol. Ther. (2002) [Pubmed]
  34. Drug-drug interactions involving antidepressants: focus on venlafaxine. Ereshefsky, L. Journal of clinical psychopharmacology. (1996) [Pubmed]
  35. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. Granvil, C.P., Krausz, K.W., Gelboin, H.V., Idle, J.R., Gonzalez, F.J. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  36. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Heim, M., Meyer, U.A. Lancet (1990) [Pubmed]
  37. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. Suzuki, T., Fujita, S., Narimatsu, S., Masubuchi, Y., Tachibana, M., Ohta, S., Hirobe, M. FASEB J. (1992) [Pubmed]
  38. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Carrillo, J.A., Dahl, M.L., Svensson, J.O., Alm, C., Rodríguez, I., Bertilsson, L. Clin. Pharmacol. Ther. (1996) [Pubmed]
WikiGenes - Universities